DNA Topoisomerases, Type II
"DNA Topoisomerases, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.
Descriptor ID |
D004250
|
MeSH Number(s) |
D08.811.399.403.741
|
Concept/Terms |
DNA Topoisomerases, Type II- DNA Topoisomerases, Type II
- Type II DNA Topoisomerase
- Topoisomerase II
- DNA Topoisomerase (ATP-Hydrolysing)
- DNA Topoisomerase II
- DNA Type 2 Topoisomerase
|
Below are MeSH descriptors whose meaning is more general than "DNA Topoisomerases, Type II".
Below are MeSH descriptors whose meaning is more specific than "DNA Topoisomerases, Type II".
This graph shows the total number of publications written about "DNA Topoisomerases, Type II" by people in this website by year, and whether "DNA Topoisomerases, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2008 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Topoisomerases, Type II" by people in Profiles.
-
Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. J Hematol Oncol. 2008 Aug 14; 1:12.
-
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007 Dec; 106(2):181-9.
-
Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer. 2004 May; 40(1):19-31.